Ixazomib citrate Inhibitor

Name: Ixazomib citrate Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5759201
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759201

Ixazomib citrate is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (IC50 of 3.4nM) with potential antineoplastic activity. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Ixazomib citrate, Inhibitor

Full Product Name

Ixazomib citrate

Product Synonym Names

MLN9708

Form/Format

Solid. Powder

Purity/Purification

100.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

517.12

Solubility

DMSO: 100mg/mL (193.38mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C20H23BCl2N2O9

SMILES

CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1

CAS Number

1239908-20-3

Target & IC50

20S proteasome beta5: ic50 3.4nM
20S proteasome beta1: ic50 31nM
20S proteasome beta2: ic50 3500nM

In Vitro

In animal tumor model studies, MLN2238 is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of MLN2238 versus bortezomib showed a significantly longer survival time in mice treated with MLN2238 than mice receiving bortezomib[1].

Product Categories/Family for Ixazomib citrate, inhibitor

Proteases/Proteasome; Proteasome; Ubiquitination

Product References and Citations for Ixazomib citrate, inhibitor

Chauhan D, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.
Chauhan D, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.

Other Notes

Small volumes of Ixazomib citrate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Ixazomib citrate purchase

MBS5759201 is an inhibitor targeting Ixazomib citrate.